Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin K with genomic considerations: A pilot study

Pharmacotherapy

Volumn 33, Issue 11, 2013, Pages 1136-1146

  Bussey, Henry I ^a,b,c,d   Bussey, Marie ^d,e   Bussey Smith, Kristin L ^f   Frei, Christopher R ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ClotCare   (United States)

^d ClotCare   (United States)

^e Genesis Advanced Technologies Inc   (United States)

^f Allergy Asthma Immunology and Rheumatology Institute ^*  (United States)

Author keywords

anticoagulation; cost; genomics; home INR monitoring; self testing; vitamin K; warfarin

Indexed keywords

CYTOCHROME P450 2C9; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; DRUG INFORMATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHARMACOGENOMICS; PILOT STUDY; PREDICTION; PROSPECTIVE STUDY; SELF EVALUATION; SELF TESTING WITH ONLINE REMOTE MONITORING AND MANAGEMENT; BLOOD CLOTTING; DISEASE MANAGEMENT; DRUG EFFECTS; DRUG MONITORING; EVALUATION STUDY; GENETICS; GENOMICS; MIDDLE AGED; PROCEDURES; REMOTE SENSING; SELF CARE; STANDARDS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; DISEASE MANAGEMENT; DRUG MONITORING; FEMALE; GENOMICS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REMOTE SENSING TECHNOLOGY; SELF CARE; VITAMIN K; WARFARIN; YOUNG ADULT;

EID: 84892369024     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1343     Document Type: Article

References (31)

1. Veeger NJ, Piersma-Wichers M, Hillege HL, Crijns HJ, van der Meer J,. Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease. J Thromb Haemost 2006; 4: 1625-7.
2. Witt DM, Delate T, Clark NP, et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010; 8: 744-9.
3. Witt DM, Delate T, Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114: 952-6.
4. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ,. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127: 1515-22.
5. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-45.
6. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83.
7. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-16.
8. Koroshetz WJ,. Warfarin, aspirin, and intracranial vascular disease. N Engl J Med 2005; 352: 1368-70.
9. Connolly SJ, Pogue J, Eikelboom J, et al. on behalf of the ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-203.
10. Singer DE, Chang Y, Fang MC, et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009; 2: 297-304.
11. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E,. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
12. Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996; 27: 1349-55.
13. Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011; 154: 472-82.
14. Menendez-Jandula B, Souto JC, Oliver A, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 2005; 142: 1-10.
15. Baker WL, Cios DA, Sander SD, Coleman CI,. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 244-52.
16. Claes N, Buntinx F, Vijgen J, et al. The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial. Eur Heart J 2005; 26: 2159-65.
17. Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI,. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 2005; 25: 1746-51.
18. Rombouts EK, Rosendaal FR, Van Der Meer FJ,. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007; 5: 2043-8.
19. Sconce E, Avery P, Wynne H, Kamali F,. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109: 2419-23.
20. Oldenburg J, Watzka M, Rost S, Muller CR,. VKORC1: molecular target of coumarins. J Thromb Haemost 2007; 5 (Suppl. 1): 1-6.
21. Booth SL, Sadowski JA,. Determination of phylloquinone in foods by high-performance liquid chromatography. Methods Enzymol 1997; 282: 446-56.
22. Bussey HI,. Impact of a new method of warfarin management on patient satisfaction, time, and cost. Pharmacotherapy (in press).
23. Coumadin package insert. Princeton, NJ, Bristol-Myers Squibb. Available at http://packageinserts.bms.com/pi/pi-coumadin.pdf. Accessed July 29, 2013.
24. Ryan F, Byrne S, O'Shea S,. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an Internet-based expert system. J Thromb Haemost 2009; 7: 1284-90.
25. Harper PL, Pollock D,. Anticoagulation self-management using near patient testing and decision support software provided via an Internet Website improved anticoagulation control in patients on long-term warfarin. Blood 2008; 112:Abstract #1278.
26. Ferrando F, Mira Y, Contreras MT, Aguado C, Aznar JA,. Implementation of Sintromac Web, a new Internet-based tool for oral anticoagulation therapy telecontrol; study on consistency and patient satisfaction. Thromb Haemost 2010; 103: 1091-101.
27. Kim YI, Nieuwlaat R, Connolly SJ, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010; 8: 101-6.
28. Nieuwlaat R, Hubers LM, Spyropoulos AC, et al. Randomised comparison of a simple warfarin dosing algorithm versus a computerized anticoagulation management system for control of warfarin maintenance therapy. Thromb Haemost 2012; 108: 1228-35.
29. Poller L, Keown M, Ibrahim S, For the European Action on Anticoagulation (EAA), et al. A multicentre randomized assessment of the DAWN AC computer-assisted oral anticoagulant dosing program. Thromb Haemost 2009; 101: 487-94.
30. Sconce EA, Avery PJ, Wynne HA, Kamali F,. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. J Thromb Haemost 2008; 6: 1226-8.
31. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.